Jab1 mediates cytoplasmic localization and degradation of West Nile virus capsid protein

Wonkyung Oh, Mi Ran Yang, Eun Woo Lee, Ki Moon Park, Suhkneung Pyo, Joo Sung Yang, Han Woong Lee, Jaewhan Song

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The clinical manifestations of West Nile virus (WNV), a member of the Flavivirus family, include febrile illness, sporadic encephalitis, and paralysis. The capsid (Cp) of WNV is thought to participate in these processes by inducing apoptosis through mitochondrial dysfunction and activation of caspase-9 and caspase-3. To further identify the molecular mechanism of the WNV capsid protein (WNVCp), yeast two-hybrid assays were employed using WNV-Cp as bait. Jab1, the fifth subunit of the COP9 signalosome, was subsequently identified as a molecule that interacts with WNVCp. Immunoprecipitation and glutathione S-transferase pulldown assays confirmed that direct interaction could occur between WNVCp and Jab1. Immunofluorescence microscopy demonstrated that the overexpressed WNVCp, which localized to the nucleolus, was translocated to the cytoplasm upon its co-expression with Jab1. When treated with leptomycin B, Jab1-facilitated nuclear exclusion of WNVCp was prevented, which indicated that the CRM1 complex is required for Jab1-facilitated nuclear export of WNVCp. Moreover, Jab1 promoted the degradation of WNVCp in a proteasome-dependent way. Consistent with this, WNVCp-mediated cell cycle arrest at the G2 phase in H1299 was prevented by exogenous Jab1. Finally, an analysis of WNVCp deletion mutants indicated that the first 15 amino acids were required for interaction with Jab1. Furthermore, the double-point mutant of the WNVCp, P5A/P8A, was incapable of binding to Jab1. These results indicate that Jab1 has a potential protective effect against pathogenic WNVCp and might provide a novel target site for the treatment of disease caused by WNV.

Original languageEnglish
Pages (from-to)30166-30174
Number of pages9
JournalJournal of Biological Chemistry
Volume281
Issue number40
DOIs
Publication statusPublished - 2006 Oct 6

Fingerprint

West Nile virus
Capsid Proteins
Viruses
Degradation
Capsid
Assays
Flavivirus
Two-Hybrid System Techniques
Cell Nucleus Active Transport
Caspase 9
G2 Phase
Encephalitis
Proteasome Endopeptidase Complex
Cell Cycle Checkpoints
Glutathione Transferase
Fluorescence Microscopy
Immunoprecipitation
Caspase 3
Paralysis
Yeast

All Science Journal Classification (ASJC) codes

  • Biochemistry

Cite this

Oh, Wonkyung ; Yang, Mi Ran ; Lee, Eun Woo ; Park, Ki Moon ; Pyo, Suhkneung ; Yang, Joo Sung ; Lee, Han Woong ; Song, Jaewhan. / Jab1 mediates cytoplasmic localization and degradation of West Nile virus capsid protein. In: Journal of Biological Chemistry. 2006 ; Vol. 281, No. 40. pp. 30166-30174.
@article{84ca796c86f34a70976230a514ea2151,
title = "Jab1 mediates cytoplasmic localization and degradation of West Nile virus capsid protein",
abstract = "The clinical manifestations of West Nile virus (WNV), a member of the Flavivirus family, include febrile illness, sporadic encephalitis, and paralysis. The capsid (Cp) of WNV is thought to participate in these processes by inducing apoptosis through mitochondrial dysfunction and activation of caspase-9 and caspase-3. To further identify the molecular mechanism of the WNV capsid protein (WNVCp), yeast two-hybrid assays were employed using WNV-Cp as bait. Jab1, the fifth subunit of the COP9 signalosome, was subsequently identified as a molecule that interacts with WNVCp. Immunoprecipitation and glutathione S-transferase pulldown assays confirmed that direct interaction could occur between WNVCp and Jab1. Immunofluorescence microscopy demonstrated that the overexpressed WNVCp, which localized to the nucleolus, was translocated to the cytoplasm upon its co-expression with Jab1. When treated with leptomycin B, Jab1-facilitated nuclear exclusion of WNVCp was prevented, which indicated that the CRM1 complex is required for Jab1-facilitated nuclear export of WNVCp. Moreover, Jab1 promoted the degradation of WNVCp in a proteasome-dependent way. Consistent with this, WNVCp-mediated cell cycle arrest at the G2 phase in H1299 was prevented by exogenous Jab1. Finally, an analysis of WNVCp deletion mutants indicated that the first 15 amino acids were required for interaction with Jab1. Furthermore, the double-point mutant of the WNVCp, P5A/P8A, was incapable of binding to Jab1. These results indicate that Jab1 has a potential protective effect against pathogenic WNVCp and might provide a novel target site for the treatment of disease caused by WNV.",
author = "Wonkyung Oh and Yang, {Mi Ran} and Lee, {Eun Woo} and Park, {Ki Moon} and Suhkneung Pyo and Yang, {Joo Sung} and Lee, {Han Woong} and Jaewhan Song",
year = "2006",
month = "10",
day = "6",
doi = "10.1074/jbc.M602651200",
language = "English",
volume = "281",
pages = "30166--30174",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "40",

}

Jab1 mediates cytoplasmic localization and degradation of West Nile virus capsid protein. / Oh, Wonkyung; Yang, Mi Ran; Lee, Eun Woo; Park, Ki Moon; Pyo, Suhkneung; Yang, Joo Sung; Lee, Han Woong; Song, Jaewhan.

In: Journal of Biological Chemistry, Vol. 281, No. 40, 06.10.2006, p. 30166-30174.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Jab1 mediates cytoplasmic localization and degradation of West Nile virus capsid protein

AU - Oh, Wonkyung

AU - Yang, Mi Ran

AU - Lee, Eun Woo

AU - Park, Ki Moon

AU - Pyo, Suhkneung

AU - Yang, Joo Sung

AU - Lee, Han Woong

AU - Song, Jaewhan

PY - 2006/10/6

Y1 - 2006/10/6

N2 - The clinical manifestations of West Nile virus (WNV), a member of the Flavivirus family, include febrile illness, sporadic encephalitis, and paralysis. The capsid (Cp) of WNV is thought to participate in these processes by inducing apoptosis through mitochondrial dysfunction and activation of caspase-9 and caspase-3. To further identify the molecular mechanism of the WNV capsid protein (WNVCp), yeast two-hybrid assays were employed using WNV-Cp as bait. Jab1, the fifth subunit of the COP9 signalosome, was subsequently identified as a molecule that interacts with WNVCp. Immunoprecipitation and glutathione S-transferase pulldown assays confirmed that direct interaction could occur between WNVCp and Jab1. Immunofluorescence microscopy demonstrated that the overexpressed WNVCp, which localized to the nucleolus, was translocated to the cytoplasm upon its co-expression with Jab1. When treated with leptomycin B, Jab1-facilitated nuclear exclusion of WNVCp was prevented, which indicated that the CRM1 complex is required for Jab1-facilitated nuclear export of WNVCp. Moreover, Jab1 promoted the degradation of WNVCp in a proteasome-dependent way. Consistent with this, WNVCp-mediated cell cycle arrest at the G2 phase in H1299 was prevented by exogenous Jab1. Finally, an analysis of WNVCp deletion mutants indicated that the first 15 amino acids were required for interaction with Jab1. Furthermore, the double-point mutant of the WNVCp, P5A/P8A, was incapable of binding to Jab1. These results indicate that Jab1 has a potential protective effect against pathogenic WNVCp and might provide a novel target site for the treatment of disease caused by WNV.

AB - The clinical manifestations of West Nile virus (WNV), a member of the Flavivirus family, include febrile illness, sporadic encephalitis, and paralysis. The capsid (Cp) of WNV is thought to participate in these processes by inducing apoptosis through mitochondrial dysfunction and activation of caspase-9 and caspase-3. To further identify the molecular mechanism of the WNV capsid protein (WNVCp), yeast two-hybrid assays were employed using WNV-Cp as bait. Jab1, the fifth subunit of the COP9 signalosome, was subsequently identified as a molecule that interacts with WNVCp. Immunoprecipitation and glutathione S-transferase pulldown assays confirmed that direct interaction could occur between WNVCp and Jab1. Immunofluorescence microscopy demonstrated that the overexpressed WNVCp, which localized to the nucleolus, was translocated to the cytoplasm upon its co-expression with Jab1. When treated with leptomycin B, Jab1-facilitated nuclear exclusion of WNVCp was prevented, which indicated that the CRM1 complex is required for Jab1-facilitated nuclear export of WNVCp. Moreover, Jab1 promoted the degradation of WNVCp in a proteasome-dependent way. Consistent with this, WNVCp-mediated cell cycle arrest at the G2 phase in H1299 was prevented by exogenous Jab1. Finally, an analysis of WNVCp deletion mutants indicated that the first 15 amino acids were required for interaction with Jab1. Furthermore, the double-point mutant of the WNVCp, P5A/P8A, was incapable of binding to Jab1. These results indicate that Jab1 has a potential protective effect against pathogenic WNVCp and might provide a novel target site for the treatment of disease caused by WNV.

UR - http://www.scopus.com/inward/record.url?scp=33749559162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749559162&partnerID=8YFLogxK

U2 - 10.1074/jbc.M602651200

DO - 10.1074/jbc.M602651200

M3 - Article

VL - 281

SP - 30166

EP - 30174

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 40

ER -